Edition:
United States

Albany Molecular Research Inc (AMRI.OQ)

AMRI.OQ on NASDAQ Stock Exchange Global Select Market

21.71USD
23 Jun 2017
Change (% chg)

$0.03 (+0.14%)
Prev Close
$21.68
Open
$21.68
Day's High
$21.72
Day's Low
$21.63
Volume
334,918
Avg. Vol
312,573
52-wk High
$22.17
52-wk Low
$12.51

Latest Key Developments (Source: Significant Developments)

Albany Molecular says Co required to pay $35 mln termination fee to GTCR, Carlyle, if GTCR, Carlyle terminate deal
Tuesday, 6 Jun 2017 09:25am EDT 

June 6 (Reuters) - Albany Molecular Research Inc :Albany molecular research inc - co required to pay $35 million termination fee to gtcr, carlyle if gtcr, carlyle terminate deal - sec filing.Albany molecular research- deal with gtcr, carlyle provides that gtcr, carlyle shall pay co $70 million termination fee if amri terminates deal.  Full Article

AMRI to be acquired by the Carlyle Group and GTCR
Tuesday, 6 Jun 2017 07:30am EDT 

June 6 (Reuters) - Albany Molecular Research Inc :AMRI signs definitive agreement to be acquired by the Carlyle Group and GTCR for $21.75 per share in cash.Deal for ‍$21.75 per share in cash.​.Transaction will be financed through a combination of debt and equity financing.Agreement was unanimously approved by AMRI's board of directors which has recommended that shareholders vote in favor of transaction.There is no financing condition to obligations of equity sponsors to consummate transaction​.Carlyle and GTCR have received debt financing commitments to finance transaction.  Full Article

Amri Q1 non-gaap earnings per share $0.13
Tuesday, 9 May 2017 07:30am EDT 

May 9 (Reuters) - Albany Molecular Research Inc ::Albany Molecular Research Inc - company confirms 2017 financial guidance.Amri announces first quarter 2017 results.Q1 non-gaap earnings per share $0.13.Q1 loss per share $0.25.Q1 revenue rose 55 percent to $163.8 million.Q1 earnings per share view $0.12 -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $1.16, revenue view $720.5 million -- Thomson Reuters I/B/E/S.  Full Article

Denovo Biopharma obtains exclusive license to Liafensine from AMRI
Monday, 24 Apr 2017 07:00am EDT 

April 24 (Reuters) - Denovo Biopharma::Denovo Biopharma obtains exclusive license to Liafensine from AMRI.Denovo Biopharma - under terms, Denovo Biopharma gains an exclusive license to all rights to develop, manufacture and commercialize Liafensine globally.Denovo Biopharma - Liafensine was well tolerated, with no evidence of dose-dependent discontinuations due to adverse events.Denovo Biopharma - Liafensine program was not continued beyond phase 2 studies.  Full Article

Albany Molecular Research files for secondary offering of 2.2 mln shares
Friday, 17 Mar 2017 12:06pm EDT 

Albany Molecular Research Inc :Files to say selling stockholders may offer and sell up to 2.2 million shares of co's common stock - SEC filing.  Full Article

Albany Molecular Research enters into agreement with pharmaceutical group Ferrer, Accord Healthcare
Tuesday, 21 Feb 2017 08:05am EST 

Albany Molecular Research Inc : Albany Molecular Research Inc - entered into an agreement with pharmaceutical group Ferrer and Accord Healthcare, Inc. . Albany Molecular - agreement to develop, manufacture undisclosed complex parenteral drug product for registration, subsequent commercialization in u.s. . Albany molecular - under terms, amri to work with ferrer to develop, initially provide cgmp manufacturing, analytical support for registration of new product .Albany molecular research inc - accord healthcare to be responsible for advancing product candidate through regulatory submission, commercialization.  Full Article

AMRI posts Q4 adj. earnings per share $0.34
Tuesday, 21 Feb 2017 07:28am EST 

Albany Molecular Research Inc : AMRI announces fourth quarter and full year 2016 results and provides 2017 outlook . Q4 non-GAAP earnings per share $0.34 . Q4 loss per share $0.37 . Q4 revenue rose 51 percent to $191.3 million . Q4 earnings per share view $0.48 -- Thomson Reuters I/B/E/S . Sees 2017 non-GAAP diluted EPS $1.08 to $1.20 . Sees 2017 GAAP diluted loss per share $0.28 to $0.16 . FY2017 earnings per share view $1.30, revenue view $763.3 million -- Thomson Reuters I/B/E/S . Albany Molecular Research Inc - sees 2017 capital expenditures $35 million to $40 million .Albany Molecular Research Inc sees 2017 revenue $710 million to $740 million.  Full Article

Amri Q3 non-gaap EPS $0.17
Tuesday, 8 Nov 2016 07:30am EST 

Albany Molecular Research Inc : Reaffirms 2016 outlook . Albany molecular research inc sees full year 2016 capital expenditures of approximately $48 million . Fy2016 earnings per share view $1.08 -- Thomson Reuters I/B/E/S . Amri announces third quarter 2016 results . Q3 non-gaap earnings per share $0.17 . Q3 loss per share $0.57 . Q3 revenue rose 46 percent to $152.7 million . Q3 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees fy 2016 non-gaap earnings per share $1.03 to $1.11 .Sees fy 2016 revenue $590 million to $615 million.  Full Article

Albany Molecular files for secondary offering of 7 million shares of its common stock
Friday, 23 Sep 2016 04:32pm EDT 

Albany Molecular Research Inc :Albany Molecular files for secondary offering of 7 million shares of its common stock - SEC filing.  Full Article

Albany Molecular Research announces restructuring plan of certain operations in U.S.and Europe
Monday, 29 Aug 2016 05:19pm EDT 

Albany Molecular Research Inc : Announced a restructuring plan with respect to certain operations in United States and Europe . Restructuring plan in connection with previously announced acquisition of prime European therapeuticals S.P.A Euticals . Under plan, co expects to incur certain charges related to reduction in force, other transition activities between $5.7 - $7.3 million . Cash charges will consist of $5.5 - $7.1 million of employee and other related costs and will primarily be paid during second half of 2016 .Company expects majority of these charges to be recorded in second half of 2016..  Full Article

More From Around the Web

Photo

GTCR, Carlyle to buy contract research firm Albany Molecular

Contract drug manufacturer and research company Albany Molecular Research Inc said on Tuesday it had agreed to be taken private by buyout firms Carlyle Group LP and GTCR LLC for about $922 million in cash.